Owing to the propensity for visual loss, immunosuppressive treatment in the form of systemic and/or local therapy is often required for the management of noninfective intermediate and posterior ...

Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

Expert Rev Ophthalmol. 2008;3(4):449-456. Infliximab is a monoclonal human-murine chimeric antibody. Since it is a chimeric antibody, infliximab is usually given concomitantly with a second agent, ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

Posterior segment non-infectious uveitis (NIPU) is a chronic, inflammatory disease affecting the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in ...

An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, ...

Early IOP safety data are encouraging for Medidur, a treatment for posterior uveitis in phase 3 trial, pSivida announced in a press release. At 3 months, only 4% more study eyes demonstrated elevated ...